Ensysce Biosciences (ENSC) Convertible Debt (2020 - 2021)
Ensysce Biosciences (ENSC) posted quarterly Convertible Debt of $5.0 million for Q4 2021, up 645.98% year-over-year from $670262.0 in Q4 2020, and little changed quarter-over-quarter from $5.0 million in Q3 2021.
Ensysce Biosciences (ENSC) Convertible Debt (2020 - 2021) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Convertible Debt for 2 consecutive years, with $5.0 million the latest figure, recorded in Q4 2021.
- In Q4 2021, Convertible Debt rose 645.98% year-over-year to $5.0 million; the TTM figure through Dec 2021 stood at $5.0 million (up 645.98% YoY), while the FY2021 annual figure was $5.0 million, up 645.98% from the prior year.
- Convertible Debt was little changed at $5.0 million in Q4 2021 per ENSC's latest filing, from $5.0 million in the prior quarter.
- Across five years, Convertible Debt topped out at $5.0 million in Q3 2021 and bottomed at $670262.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - |
| 10 | Ensysce Biosciences | 927,560.60 | -3.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 5.00 Mn |
| Sep 30, 2021 | 5.00 Mn |
| Dec 31, 2020 | 670,262.00 |
| Mar 31, 2020 | 1.00 Mn |